PharmaEssentia Corporation — Investor Relations & Filings
PharmaEssentia Corporation is a fully integrated global entity focused on the discovery, development, and commercialization of novel therapies for hematologic diseases and oncology. The company leverages a proprietary PEGylation technology platform to engineer long-acting protein therapeutics designed to improve patient outcomes. Its flagship product, BESREMi® (Ropeginterferon alfa-2b), represents a significant advancement in the treatment of Polycythemia Vera, having received regulatory approval from the US FDA and EU EMA as a first-line therapy. PharmaEssentia operates a comprehensive value chain, including internal R&D, clinical trial management, and cGMP-certified manufacturing facilities. By addressing unmet medical needs in rare blood disorders and various cancers, the company aims to deliver best-in-class treatments to global markets through its integrated research and production capabilities.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 115年04月內部人持股異動(事後) | 2026-05-05 | Chinese | |
| 115年04月董事會成員及持股 | 2026-05-05 | Chinese | |
| 本公司就撤仲案向德國聯邦最高法院提出上訴 | 2026-05-03 | Chinese | |
| 本公司受邀參加永豐金證券舉辦之法人說明會 | 2026-04-30 | Chinese | |
| 115年05月法人說明會簡報 | 2026-04-30 | Chinese | |
| 115年4月28日內部人設質解質 | 2026-04-29 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 41459336 | 115年04月內部人持股異動(事後) | 2026-05-05 | Chinese | ||
| 41456974 | 115年04月董事會成員及持股 | 2026-05-05 | Chinese | ||
| 40262270 | 本公司就撤仲案向德國聯邦最高法院提出上訴 | 2026-05-03 | Chinese | ||
| 39868460 | 本公司受邀參加永豐金證券舉辦之法人說明會 | 2026-04-30 | Chinese | ||
| 39868469 | 115年05月法人說明會簡報 | 2026-04-30 | Chinese | ||
| 38341454 | 115年4月28日內部人設質解質 | 2026-04-29 | Chinese | ||
| 37414903 | 115年年報及股東會資料 — 2026_6446_20260528F13.pdf | 2026-04-27 | Chinese | ||
| 37414833 | 115年年報及股東會資料 — 2026_6446_20260528FE1.pdf | 2026-04-27 | English | ||
| 37414808 | 115年年報及股東會資料 — 2026_6446_20260528F01.pdf | 2026-04-27 | Chinese | ||
| 37415357 | 115年年報及股東會資料 — 2026_6446_20260528FE2.pdf | 2026-04-27 | English | ||
| 37415315 | 115年年報及股東會資料 — 2026_6446_20260528F02.pdf | 2026-04-27 | Chinese | ||
| 36876006 | 說明本公司撤仲案進度 | 2026-04-26 | Chinese | ||
| 35221775 | 公告本公司台中廠已獲越南衛生部藥品管理局（DAV） 認定通過優良製造規範（GMP） | 2026-04-22 | Chinese | ||
| 33966999 | 媒體報導說明 | 2026-04-10 | Chinese | ||
| 33899667 | 公告本公司董事會決議於美國波多黎各投資設立第二間子公司 | 2026-04-09 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
PharmaEssentia Corporation via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52565/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52565 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52565 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52565 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52565}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for PharmaEssentia Corporation (id: 52565)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.